Insider trade

Avantor (AVTR): Director bought ~$204K

Simon Dingemans, Director at Avantor, bought ~$204K of Avantor shares.

~$204K
Approx. value · 25K sh @ $8.14
25K
Holds after · shares reported
Traded
May 1, 2026
Filed
May 5, 2026

What stands out in this filing

  • Simon Dingemans's first open-market purchase of AVTR in filings since 2019.
  • After this purchase the filing reports 25,000 shares, held indirectly.
  • 25,000 shares at an average of $8.14 each, as reported on the form.
  • 1 other insider at AVTR also bought in the open market within 30 days.
  • AVTR closed at $7.96 on May 1, 2026, 7% above its 52-week low and 49% below its high, after a 5% rise over the previous 30 trading days.

Calculated by OQRO from this filing and the public records it holds. Facts about the record, not a reason for the trade and not a signal.

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Mar 10, 2026InsiderDirector purchased ~$1M of AVTR shares in the open market
  2. Mar 26, 2026Company filing · Form 8-K · Executive change, Reg FDChanged a top executive or board member, and shared information with investors“On March 26, 2026, Mr. R. Brent Jones notified Avantor, Inc. (the “Company”) of his decision to resign as the Company’s Executive Vice President and Chief Financial Officer (“CFO”) to join a company outside the life sciences industry.”
  3. Apr 17, 2026Company filing · Form 8-K · Executive change, Reg FDChanged a top executive or board member, and shared information with investors“On April 17, 2026, Avantor, Inc. (the “Company”) informed Benoit Gourdier, the Company’s Executive Vice President, Bioscience and Medtech Products, that he would be transitioning to a new role supporting the Company’s segment integration activities, after which it is expected that he would depart the Company no later than December 31, 2026.”
  4. Apr 17, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“On April 23, 2026, Avantor, Inc. (the “Company”) filed a Current Report on Form 8-K (the “Original 8-K”) disclosing that Benoit Gourdier, the Company’s Executive Vice President, Bioscience and Medtech Products, would transition to a new role supporting the Company’s segment integration activities for a period of time, after which he would depart the Company.”
  5. Apr 29, 2026Company filing · Form 8-K · ResultsReported its results
  6. May 1, 2026 · this disclosureInsider · Their first buy on recordDirector purchased ~$204K of AVTR shares in the open market

What came next

  1. May 8, 2026InsiderDirector purchased ~$83K of AVTR shares in the open market
  2. Jul 14, 2026Company filing · Form 8-K · Material agreement, New debtSigned an important agreement, and took on new debt or obligations
  3. Jul 29, 2026Company filing · Form 8-K · ResultsReported its results
View the official recordSEC Form 4

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Avantor

For Avantor, OQRO holds 1 fund holdings report (13F) and 1 federal contract award dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its AVTR page.

How this filing works

Explore the data

Common questions

Which Avantor (AVTR) insider traded, and how much?

Simon Dingemans, Director at Avantor, bought ~$204K of Avantor shares. 25K shares at $8.14, open market.

When did it happen, and when was it made public?

Traded: May 1, 2026. Filed: May 5, 2026. That is 4 days between the two dates.

What stands out in this filing?

Simon Dingemans's first open-market purchase of AVTR in filings since 2019. After this purchase the filing reports 25,000 shares, held indirectly. 25,000 shares at an average of $8.14 each, as reported on the form.

Is the dollar amount exact?

It is the number of shares multiplied by the price the insider reported on the form. A grant, a gift or an option exercise has no market price, so those show shares only.

Where does this information come from?

From the SEC Form 4, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.

What else has been disclosed about Avantor recently?

For Avantor, OQRO holds 1 fund holdings report (13F) and 1 federal contract award dated in the last 90 days. They are listed on the AVTR page.

Does this mean AVTR stock is a buy or a sell?

No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.

Is OQRO free?

Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.

Other disclosures at Avantor

Everything OQRO holds on this company is on its AVTR page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

OQRO is free for everyone. No card, no trial

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data